Predicting Recurrence in Early HR+/HER2- Breast Cancer
Part of Cancer, Skin clinical trials.
This study is looking at whether certain patient information can help predict if HR+/HER2- early breast cancer will come back. If you have had surgery and hormone therapy, your data might help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of breast cancer called invasive ductal or lobular carcinoma, confirmed by biopsy.
- Your cancer should be HR-positive (hormone receptor positive) and HER2-negative, meaning it has receptors for estrogen or progesterone but not the HER2 protein.
- You need to have had standard surgery and received hormone therapy (like tamoxifen or an aromatase inhibitor) after your surgery or before.
- Your medical records must be complete and available for this study (no missing test results or follow-up visits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
This study looks at medical records of people with a common type of early breast cancer to understand how often the cancer comes back after surgery. It helps doctors learn more about which patients might have a higher or lower risk of recurrence.
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
This study follows patients with HER2-positive breast cancer who received chemotherapy and a targeted drug (trastuzumab) before surgery but did not have a complete response. Researchers want to understand which follow-up treatments work best to prevent cancer from coming back.
This study looks at women with HER2-positive breast cancer who will get chemotherapy before surgery. The goal is to find out what factors might increase the chance of the cancer spreading to the brain later on.
Hear when a new Breast Cancer, HR+/HER2- Early-Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.